Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects
The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis
Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …
Emerging topical and systemic JAK inhibitors in dermatology
F Solimani, K Meier, K Ghoreschi - Frontiers in immunology, 2019 - frontiersin.org
Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …
JAK inhibitors in dermatology: the promise of a new drug class
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–
signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling …
signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling …
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
Background Despite unmet need, 15 years have passed since a topical therapy with a new
mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) …
mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) …
The JAK-STAT pathway: impact on human disease and therapeutic intervention
JJ O'Shea, DM Schwartz, AV Villarino… - Annual review of …, 2015 - annualreviews.org
The Janus kinase (JAK)–signal transducer of activators of transcription (STAT) pathway is
now recognized as an evolutionarily conserved signaling pathway employed by diverse …
now recognized as an evolutionarily conserved signaling pathway employed by diverse …
Selective JAKinibs: prospects in inflammatory and autoimmune diseases
AT Virtanen, T Haikarainen, J Raivola, O Silvennoinen - BioDrugs, 2019 - Springer
Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers
and Activators of Transcription) pathway, play a central role in the pathogenesis of …
and Activators of Transcription) pathway, play a central role in the pathogenesis of …
Targeting the Janus kinase family in autoimmune skin diseases
Autoimmune skin diseases are characterized by significant local and systemic inflammation
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …